ArticleNew microbes and new infections2020
Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world.
Article in New microbes and new infections, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.
- Hydroxychloroquine in the treatment of coronavirus disease 2019: Rapid updated systematic review and meta-analysis.Reviews in medical virology · 2022Pooled it
- Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis.Journal of general internal medicine · 2020Pooled it
- Comprehensive evaluation of six interventions for hospitalized patients with COVID-19: A propensity score matching study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidence.History and philosophy of the life sciences · 2022Article
- Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture.Communications biology · 2022Article
- AMMI Canada Practice Point: Treatments for adults with COVID-19 in 2021-2022.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2022Article
- Review
- Drug safety of frequently used drugs and substances for self-medication in COVID-19.Therapeutic advances in drug safety · 2022Review
- SARS-CoV-2, Zika viruses and mycoplasma: Structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases.Biochimica et biophysica acta. Molecular basis of disease · 2021Article
- Moments in autophagy and disease: Past and present.Molecular aspects of medicine · 2021Review
- Efficacy of chloroquine and hydroxychloroquine for the treatment of hospitalized COVID-19 patients: a meta-analysis.Future virology · 2021Review
- Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.Lancet regional health. Americas · 2021Article
- Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020.Journal of clinical medicine · 2021Article
- NMNI editorial report, 2020.New microbes and new infections · 2021Article
- Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.Microbial drug resistance (Larchmont, N.Y.) · 2021Review
- Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2021Review
- Familiar Dermatologic Drugs as Therapies for COVID-19.Actas dermo-sifiliograficas · 2021Review
- Molecular mechanism, diagnosis, and potential treatment for novel coronavirus (COVID-19): a current literature review and perspective.3 Biotech · 2021Review
- Current Updates on Naturally Occurring Compounds Recognizing SARS-CoV-2 Druggable Targets.Molecules (Basel, Switzerland) · 2021Review
- An updated systematic review and network meta-analysis of 25 randomized trials assessing the efficacy and safety of treatments in COVID-19 disease.Journal of public health research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the context of the current coronavirus disease 2019 (COVID-19) pandemic, we conducted a meta-analysis on the effects of chloroquine derivatives in patients, based on unpublished and published reports available publicly on the internet as of 27 May 2020. The keywords 'hydroxychloroquine', 'chloroquine', 'coronavirus', 'COVID-19' and 'SARS-Cov-2' were used in the PubMed, Google Scholar and Google search engines without any restrictions as to date or language. Twenty studies were identified involving 105 040 patients (19 270 treated patients) from nine countries (Brazil, China, France, Iran, Saudi Arabia, South Korea, Spain and the USA). Big data observational studies were associated with conflict of interest, lack of treatment dosage and duration, and absence of favourable outcome. Clinical studies were associated with favourable outcomes and details on therapy. Among clinical studies, three of four randomized controlled trials reported a significant favourable effect. Among clinical studies, a significant favourable summary effect was observed for duration of cough (OR 0.19, p 0.00003), duration of fever (OR 0.11, p 0.039), clinical cure (OR 0.21, p 0.0495), death (OR 0.32, p 4.1 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.